<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02473146</url>
  </required_header>
  <id_info>
    <org_study_id>2014-001395-65</org_study_id>
    <nct_id>NCT02473146</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4</brief_title>
  <acronym>ALFA1401</acronym>
  <official_title>Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose : The main objective of this study is to assess the efficacy and tolerance of the
      addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition
      with standard doses of Ara-C in previously untreated patients aged 60 to 80 years with de
      novo acute myeloblastic leukemia (AML) and non adverse cytogenetics. The main end point for
      efficacy is 2 years-event free survival. The secondary efficacy endpoints are CR/Cri rates,
      cumulative incidence of relapse and overall survival. The secondary endpoints for safety are
      early death rate (before day 30 and 60), grade 3 to 5 adverse events and severe adverse
      events, cardiac toxicity and quality of life. Additional secondary endpoints are treatment by
      covariate interactions with respect to biological characteristics present at diagnosis (CD33
      positivity, cytogenetic, molecular abnormalities) or after treatment (Minimal residual
      disease levels). This study is an exploratory study. Patients will be allocated at inclusion
      with a 2/1 ratio either to receive treatment with GO and cytarabine or Idarubicin and
      cytarabine in a 3+7 regimen similar to the &quot;backbone&quot; ALFA 1200 scheme used concurrently by
      the ALFA group as treatment of AML patients aged &gt;60 years.

      Primary objective. The primary objective is to assess the efficacy of two doses of Gemtuzumab
      ozogamicin (GO) during induction and one dose of GO during first consolidation in combination
      with Cytarabine in elderly patients with AML in the non adverse cytogenetics-risk group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFS (defined as the time from randomization to the date of assessment of response if CR or Cri had not been achieved, relapse or death)</measure>
    <time_frame>5 years</time_frame>
    <description>Endoint for the primary objective of efficacy is EFS defined as the time from randomization to the date of assessment of response if CR or Cri had not been achieved, relapse or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite measure for Efficacy assessed by CR/Cri rates, cumulative incidence of relapse, overall survival.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure for safety</measure>
    <time_frame>5 years</time_frame>
    <description>incidence of early deaths &lt; day 30 and day 60,
grade 3 to 5 adverse events and all serious adverse events during induction and consolidation treatment
cardiac toxicity evaluated on cardiac ejection function evaluation by echocardiography or isotopic measure.
Quality of life measured by questionaries' EORTC QLQ-C30 repeated at diagnosis, after induction treatment, after the two consolidations and 3 months after the end of treatment.
End points for treatment-by-covariate interactions are
at diagnosis: percentage of CD33 positivity on blast cells, measured with a standardized method, cytogenetics and most relevant molecular markers (FLT3, MLL, CEBPa, NPM1, DNMT3a.,
after induction and end of treatment: minimal residual disease determined by WT1 and/or NPM1 transcripts levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Mylotarg Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization patients in the experimental arm are assigned to receive chemotherapy with:
Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab ozogamicin (GO)</intervention_name>
    <arm_group_label>Mylotarg Arm</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a morphologically proven diagnosis AML and both the following criteria:

          -  Age ≥ 60 years and &lt; 80 years.

          -  Not previously treated for their disease.

          -  With favourable or intermediate-risk cytogenetics. (Patients with urgent clinical need
             to begin treatment might be included before cytogenetic results, when necessary if
             they do not respond to Hydroxyurea. Patients might be included if the cytogenetic
             results are not expected in a time limit &lt; 5 days after AML diagnosis).

          -  Fit to receive intensive chemotherapy

          -  Cardiac function determined by radionucleide or echography within normal limits.

          -  Signed informed consent

        Exclusion Criteria:

          -  M3-AML

          -  Presence of adverse cytogenetics (according to European LeukemiaNet recommendation.)
             (17) defined as one of the following abnormalities: -5/5q-, -7, t(6;9), t(v;11q23)
             excluding t(9;11), inv(3)(q21;q26.2) or t(3;3)(q21;q26.2), complex karyotype (3+
             abnormalities)

          -  Secondary AML following treatment with radiotherapy or chemotherapy.

          -  AML following previously known myeloproliferative or myelodysplastic syndrome.

          -  ECOG performance status (PS) 0 to 3

          -  Serum creatinin level &gt; or = 2.5N; AST and ALT level &gt; or = 2.5N; total bilirubin
             level &gt; or = 2N
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliette LAMBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvie CASTAIGNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assitan KONE</last_name>
    <phone>0139239775</phone>
    <email>akone@ch-versailles.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laure MORISSET</last_name>
    <phone>0139239785</phone>
    <email>lmorisset@ch-versailles.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C.H.U d'Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bérangère GRUSON</last_name>
    </contact>
    <investigator>
      <last_name>Bérangère GRUSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital V. Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad AL JIJAKI</last_name>
    </contact>
    <investigator>
      <last_name>Ahmad AL JIJAKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude GARDIN</last_name>
    </contact>
    <investigator>
      <last_name>Claude GARDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain CHANTEPIE</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain CHANTEPIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Valère MALFUSON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Valère MALFUSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecile PAUTAS</last_name>
    </contact>
    <investigator>
      <last_name>Cecile PAUTAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis CAILLOT</last_name>
    </contact>
    <investigator>
      <last_name>Denis CAILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iriné Maxime BEMBA</last_name>
    </contact>
    <investigator>
      <last_name>Iriné Maxime BEMBA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliette LAMBERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juliette LAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Huriez, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno QUESNEL</last_name>
    </contact>
    <investigator>
      <last_name>Bruno QUESNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal TURLURE</last_name>
    </contact>
    <investigator>
      <last_name>Pascal TURLURE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauris GASTAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lauris GASTAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana CARP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diana CARP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HERMINE</last_name>
    </contact>
    <investigator>
      <last_name>Olivier HERMINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Dombret, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hervé Dombret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre FENAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ollivier LEGRAND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ollivier LEGRAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier THOMAS</last_name>
    </contact>
    <investigator>
      <last_name>Xavier THOMAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre H Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie LEMASLE</last_name>
    </contact>
    <investigator>
      <last_name>Emilie LEMASLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle TAVERNIER-TARDY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle TAVERNIER-TARDY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IGR</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane DE BOTTON</last_name>
    </contact>
    <investigator>
      <last_name>Stephane DE BOTTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2015</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Ms Juliette LAMBERT</investigator_full_name>
    <investigator_title>Clinical coordinator</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>untreated</keyword>
  <keyword>60-80 years old</keyword>
  <keyword>favorable and intermediate karyotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

